ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
20 mai 2020 10h12 HE
|
BioSig Technologies, Inc.
Westport, CT, May 20, 2020 (GLOBE NEWSWIRE) -- Funding completed in subsidiary without dilution to BioSig common stockPhase II human trials for merimepodib, a broad-spectrum oral anti-viral...
FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed
18 mai 2020 08h32 HE
|
BioSig Technologies, Inc.
Westport, CT, May 18, 2020 (GLOBE NEWSWIRE) -- Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of...
ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19
14 mai 2020 08h15 HE
|
BioSig Technologies, Inc.
Westport, CT, May 14, 2020 (GLOBE NEWSWIRE) -- Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing. Even at low...
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.
07 mai 2020 15h17 HE
|
BioSig Technologies, Inc.
Westport, CT, May 07, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael Schmertzler to the Board of Directors of its...
SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients
06 mai 2020 09h00 HE
|
SetPoint Medical
VALENCIA, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has...
Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
05 mai 2020 14h09 HE
|
BioSig Technologies, Inc.
Westport, CT, May 05, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Dennis Purcell to the Board of Directors of its majority-owned...
BioSig Resumes Clinical Activities with PURE EP System
01 mai 2020 10h39 HE
|
BioSig Technologies, Inc.
Westport, CT, May 01, 2020 (GLOBE NEWSWIRE) -- Clinical support staff to return to perform elective procedures at Texas Cardiac Arrhythmia Institute as of May 4, 2020Company reconfirms its...
ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal
30 avr. 2020 09h20 HE
|
BioSig Technologies, Inc.
Westport, CT, April 30, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the...
BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19
24 avr. 2020 14h30 HE
|
BioSig Technologies, Inc.
Westport, CT, April 24, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it will be hosting an investor briefing to provide an...
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19
24 avr. 2020 09h25 HE
|
BioSig Technologies, Inc.
Westport, CT, April 24, 2020 (GLOBE NEWSWIRE) -- In vitro studies demonstrated decrease of viral production by over 98%Upon approval, clinical trial to be conducted at Mayo Clinic under the...